To cite this paper use one of the standards below:
Background:Multiple sclerosis (MS) is recognized as the most prevalent autoimmune disorder affecting the central nervous system (CNS). Natalizumab (NTZ) is among the commonly used second-line treatments, showing efficacy in decreasing MS activity in most patients. NTZ binds to the α4β1 and α4β7 integrins, inhibiting leukocyte migration through the blood-brain barrier to the CNS. Genetic factors can significantly influence the therapeutic outcomes of MS treatment. However, there are few pharmacogenetic predictors of therapeutic outcomes in the treatment of MS patients. One genetic variant associated with therapeutic response to monoclonal antibodies used in treatment is the single nucleotide polymorphism (SNP) rs1801274 in the FCGR2A gene. Therefore, this study aims to analyze the feasibility of this genetic variant as a potential pharmacogenetic predictor of therapeutic failure in Natalizumab treatment among MS patients. Methods: 104 blood samples were collected from patients admitted to two university hospitals in Rio de Janeiro, with approval from the ethics committee (CAAE: 5,782,087). Genomic DNA was extracted from leukocytes for subsequent genotyping by TaqMan-PCR assay. Results:Among the patients, 9 exhibited confirmed therapeutic failure to NTZ treatment. Following statistical analysis, a significant association was identified between the GG genotype of FCGR2A (p=0.0004, OR=0.3530) and therapeutic failure. Additionally, a higher frequency of the AG genotype was observed in patients who did not experience therapeutic failure (p=0.0002, OR=3.144). Conclusions: Previous research has posited that FCgRs may also impact the efficacy and tolerability of human monoclonal antibody strategies targeting anti-alpha-4 integrin. Given the genetic diversity of the Brazilian population due to miscegenation, our preliminary findings suggest the necessity to investigate the role of FCGR2A rs1801274 as a potential pharmacogenetic predictor for MS patient's response to NTZ.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper